DoD PRMRP Clinical Trial Award | W81XWH 22 PRMRP CTA

Opportunity Information: Apply for W81XWH 22 PRMRP CTA

The DoD PRMRP Clinical Trial Award (FY22 PRMRP CTA; Funding Opportunity Number W81XWH-22-PRMRP-CTA) is a Department of Defense research funding opportunity run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Peer Reviewed Medical Research Program (PRMRP). Its core purpose is to fund the rapid launch and execution of clinical trials that could meaningfully change outcomes for diseases or conditions that fall within the congressionally directed FY22 PRMRP Topic Areas and align with the FY22 PRMRP Strategic Goals. In practical terms, the program is looking for trials that are ready to move forward and have a clear path to producing results that matter to patients and clinical practice, rather than exploratory laboratory work.

This award is specifically for human clinical trials, and the funding must be used to support a clinical trial as defined by the sponsor: a research study where one or more human participants are prospectively assigned to one or more interventions (including placebo or other controls) in order to measure the effects on biomedical or behavioral health-related outcomes. The announcement makes a point of drawing a firm boundary between clinical trials and preclinical research; investigators who only have preclinical aims are directed to consider other FY22 PRMRP award mechanisms instead. Applicants are also pointed to the DoD Human Subjects Resource Document for guidance on human-subjects expectations and requirements, which is often central to DoD-sponsored clinical research planning and compliance.

In terms of what the trial can test, the scope is broad as long as it fits the PRMRP topic priorities. Eligible interventions may include promising new products, drugs or biologics, medical devices, clinical guidance or practice approaches, and emerging technologies. The program is flexible about trial stage and scale: proposals can range from small proof-of-concept efforts (such as pilot studies, first-in-human trials, or phase 0 work) intended to demonstrate feasibility or shape the design of later studies, all the way to larger trials designed to determine efficacy in the target patient population. That range signals that the opportunity is not limited to late-stage pivotal studies, but it does expect applicants to be prepared for real-world clinical trial execution, including prospective assignment and measurable health outcomes.

Administratively, the opportunity falls under the category of discretionary funding and may be issued as either a grant or a cooperative agreement, meaning some awards may involve more substantial government involvement or coordination depending on the project needs and structure. The CFDA (Assistance Listing) number associated with this opportunity is 12.420, which corresponds to Department of Defense medical research programs. Eligibility is listed as unrestricted, indicating that a wide variety of applicant organizations may apply (for example, academic institutions, nonprofits, for-profits, and other entities), subject to any additional eligibility clarifications contained in the full solicitation text. The posting lists an expected eight awards. The public notice shows an award ceiling of 0, which typically means the ceiling was not specified in that summary field and applicants would need to consult the full announcement for budget limits, caps, and any cost constraints.

Key dates provided in the source are a creation/posting date of March 16, 2022 and an original closing date of August 12, 2022. Anyone looking to apply (or to understand how future PRMRP CTAs tend to be structured) would also be directed to the PRMRP funding portal for related mechanisms and to confirm current topic areas, strategic goals, and detailed submission requirements.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD PRMRP Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Mar 16, 2022.
• Applicants must submit their applications by Aug 12, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 PRMRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: